Patient-Focused Support: How Gov’t Affairs & Public Policy Groups Support the Patient Journey

STUDY OVERVIEW

Patient engagement is a critical success factor in the pharmaceutical sector today, and Government Affairs and Public Policy are among the many functions conducting activities and initiatives to positively impact the "patient journey.”

This study examines key support tactics and activities by which leading Government Affairs and Public Policy groups support patients. In particular, this study includes insights and metrics around the activities, timing and funding involvement of Government Affairs and Public Policy groups insofar as patient-oriented programs.


KEY TOPICS

• Patient-Focused Support: Activities & Timing
• Patient-Focused Support: Funding

• Product types that GA&PP group conducts most of its patient engagement activities for
• Primary therapeutic areas that GA&PP conducts patient engagement activities in
• Patient-focused activities and programs your GA&PP group manages and supports
• Phase of the patient journey during which GA&PP conducts engagement activities
• Best Practices for GA&PP to effectively engage patients along the different patient journey phases
• Does GA&PP budget include funds for patient engagement activities
• Approximately what percentage of your GA&PP budget is allocated to patient engagement initiatives, activities and programs
• Approximately what was the total GA&PP investment for patient engagement initiatives

• Companies focus their patient support programs almost entirely around products that treat chronic care conditions. Overall, 75% companies treat chronic care conditions where ongoing support is essential to the long-term well-being of patients.
• Some 25% supporting a mix of both chronic and short-term care products, while no organizations support short-term care conditions alone.

Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Chemical; Technology; Health Care; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Boehringer Ingelheim; Janssen; Roche; BD; Abbott; Abbvie; Astellas; AstraZeneca; Genentech; UCB Pharma; GlaxoSmithKline ; Sanofi; Teva Pharmaceutical Industries Ltd; Dr Reddy's Laboratories; Shire

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.